Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial

• Published in: Annals of hematology 2015-04, Vol.94 (4), p.593-601
• Main Authors: Wasle, Ines, Gamerith, Gabriele, Kocher, Florian, Mondello, Patrizia, Jaeger, Thomas, Walder, Alois, Auberger, Jutta, Melchardt, Thomas, Linkesch, Werner, Fiegl, Michael, Mian, Michael
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic - therapeutic use; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; Drug-Related Side Effects and Adverse Reactions - epidemiology; Female; Hematology; Humans; Lymphoma - drug therapy; Lymphoma - epidemiology; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Polyethylene Glycols - therapeutic use; Retrospective Studies; Treatment Outcome
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-014-2250-6

The anthracycline doxorubicin plays a major role in the treatment of lymphoproliferative disorders. However, its use is often limited due to cardiac toxicity, which seems to be much less in the liposomal non-pegylated formulation (Myocet®). The aim of this study was the evaluation of efficacy and toxicity of Myocet®-containing treatment regimens, with a focus on cardiotoxicity during treatment in lymphoma patients. A total of 326 consecutive patients, treated between March 2008 and December 2013 in 11 Austrian and 1 Italian cancer centers, were retrospectively assessed. Patients’ baseline and treatment-related parameters were obtained by reviewing hospital records. Median age was 74 years (range 26–93). The most common histology was DLBCL (60 %), followed by FL (13 %) and MCL (8 %). At least one cardiovascular comorbidity was present in 72 % of patients. Most common grade 3/4 toxicities were hematologic, namely, leukopenia, neutropenia, thrombocytopenia, and febrile neutropenia in 44, 40, 17, and 16 %. Overall, 43 patients suffered a cardiac event (any grade) with most patients developing congestive heart failure. Parameters significantly associated with severe cardiac events (grades 3–5) were the presence of cardiovascular comorbidities, chronic obstructive pulmonary disease, and elevated baseline NT-proBNP. Treatment response after first line Myocet®-containing therapy was ≥58 % among all entities (range 58–86 %) and therefore comparable to those of conventional therapeutic regimens. Herein, we provide a detailed toxicity profile of Myocet®-containing chemotherapy regimens. Despite the high rate of patients with preexisting comorbidities, the number of adverse events was encouraging. However, these results need to be confirmed in a prospective randomized trial.